TORONTO, April 3, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming ...

The adoption of AI in clinical trials holds the potential to revolutionize how therapies are discovered, but the pace of that ...

Clinical trials are losing participants. Patient-first design and decentralized models can help fix the dropout problem.

In this video interview, Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher ...

Adaptive clinical trial design represents a modern approach to evaluating healthcare interventions that allows pre‐specified modifications based on accumulating data. This flexible methodology ...

Note: This is the third article of a three-part series. Real-world evidence (RWE) plays a crucial role in supporting the benefits of one drug over another in debates that play out on the boards and ...

In today's ACT Brief, we examine the technical and operational challenges of implementing risk-based monitoring across global ...

The integration of real-world data (RWD) into protocol feasibility and site selection has emerged as a clinical trial game-changer in recent years. Traditionally relying heavily on data from carefully ...

Clinical trials are the engine of modern cancer care, transforming scientific discoveries into new treatments that can save ...

Furthermore, increasing complexity in cancer clinical trial design has led to challenges such as protocol deviations, slow enrollment leading to lengthened durations of trial, and escalating costs. By ...